These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37531469)

  • 21. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
    Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
    Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1.
    Liu L; Kong M; Gassman NR; Freudenthal BD; Prasad R; Zhen S; Watkins SC; Wilson SH; Van Houten B
    Nucleic Acids Res; 2017 Dec; 45(22):12834-12847. PubMed ID: 29121337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SERious Surprises for ADP-Ribosylation Specificity: HPF1 Switches PARP1 Specificity to Ser Residues.
    Leung AK
    Mol Cell; 2017 Mar; 65(5):777-778. PubMed ID: 28257697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
    Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
    J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins.
    Alemasova EE; Lavrik OI
    Nucleic Acids Res; 2019 May; 47(8):3811-3827. PubMed ID: 30799503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PARP1/2 and Accessory Factor HPF1 Interlock to Form a Joint Active Site.
    Cancer Discov; 2020 Apr; 10(4):486. PubMed ID: 32060056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The regulatory landscape of the human HPF1- and ARH3-dependent ADP-ribosylome.
    Hendriks IA; Buch-Larsen SC; Prokhorova E; Elsborg JD; Rebak AKLFS; Zhu K; Ahel D; Lukas C; Ahel I; Nielsen ML
    Nat Commun; 2021 Oct; 12(1):5893. PubMed ID: 34625544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
    Jain PG; Patel BD
    Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response.
    Kim C; Wang XD; Yu Y
    Elife; 2020 Aug; 9():. PubMed ID: 32844745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the PARP1, ADP-Ribosylation, and TRIP12 Triad With Markers of Patient Outcome in Human Breast Cancer.
    Krishnan A; Spegg V; Dettwiler S; Schraml P; Moch H; Dedes K; Varga Z; Altmeyer M
    Mod Pathol; 2023 Jul; 36(7):100167. PubMed ID: 36990278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells.
    Kanev PB; Varhoshkova S; Georgieva I; Lukarska M; Kirova D; Danovski G; Stoynov S; Aleksandrov R
    Cell Rep; 2024 May; 43(5):114234. PubMed ID: 38758646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The CSB chromatin remodeler regulates PARP1- and PARP2-mediated single-strand break repair at actively transcribed DNA regions.
    Bilkis R; Lake RJ; Cooper KL; Tomkinson A; Fan HY
    Nucleic Acids Res; 2023 Aug; 51(14):7342-7356. PubMed ID: 37326017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA‑PKcs PARylation regulates DNA‑PK kinase activity in the DNA damage response.
    Han Y; Jin F; Xie Y; Liu Y; Hu S; Liu XD; Guan H; Gu Y; Ma T; Zhou PK
    Mol Med Rep; 2019 Oct; 20(4):3609-3616. PubMed ID: 31485633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human apurinic/apyrimidinic endonuclease 1 is modified in vitro by poly(ADP-ribose) polymerase 1 under control of the structure of damaged DNA.
    Moor NA; Vasil'eva IA; Kuznetsov NA; Lavrik OI
    Biochimie; 2020 Jan; 168():144-155. PubMed ID: 31668992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-time monitoring of PARP1-dependent PARylation by ATR-FTIR spectroscopy.
    Krüger A; Bürkle A; Hauser K; Mangerich A
    Nat Commun; 2020 May; 11(1):2174. PubMed ID: 32358582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo.
    Shao Z; Lee BJ; Rouleau-Turcotte É; Langelier MF; Lin X; Estes VM; Pascal JM; Zha S
    Nucleic Acids Res; 2020 Sep; 48(17):9694-9709. PubMed ID: 32890402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probing the Conformational Changes Associated with DNA Binding to PARP1.
    Rudolph J; Mahadevan J; Luger K
    Biochemistry; 2020 Jun; 59(21):2003-2011. PubMed ID: 32357296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The contribution of PARP1, PARP2 and poly(ADP-ribosyl)ation to base excision repair in the nucleosomal context.
    Kutuzov MM; Belousova EA; Kurgina TA; Ukraintsev AA; Vasil'eva IA; Khodyreva SN; Lavrik OI
    Sci Rep; 2021 Mar; 11(1):4849. PubMed ID: 33649352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers.
    Kamaletdinova T; Fanaei-Kahrani Z; Wang ZQ
    Cells; 2019 Dec; 8(12):. PubMed ID: 31842403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Influence of the Poly(ADP-Ribose) Polymerase 1 Level on the Status of Base Excision Repair in Human Cells].
    Ilina ES; Kochetkova AS; Belousova EA; Kutuzov MM; Lavrik OI; Khodyreva SN
    Mol Biol (Mosk); 2023; 57(2):285-298. PubMed ID: 37000656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.